Lipo Escultra weight loss dietary supplements are being recalled after federal officials discovered undeclared drug ingredients in the capsules that have been linked to life threatening side effects.
The Food and Drug Administratoin (FDA) tested Lipo Escultra diet pills, manufactured by Escultra Corp. of Brooklyn, N.Y. (dba JAT Productos Naturales Corp., and JAT Natural Products Corp.), and discovered they contain the appetite suppressant sibutramine, now a controlled substance, that was pulled from the market for safety reasons.
Sibutramine was the drug ingredient in Merida, a prescription anti-obesity drug that was pulled from the market due to health risks. It is known to substantially increase blood pressure and/or pulse rates in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). These medications can cause an increased risk of cardiovascular events, such as heart attack and strokes, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines.
Lipo Escultura is marketed as a weight loss dietary supplement. The products were sold or distributed nationwide by JAT Productos Naturales Corp. through internet sales and retail stores.
Anyone who has these products in their possession should stop taking them immediately and seek medical attention if they experience any side effects. Any adverse effects related to Lipo Escultura should be reported to the FDA MedWatch Adverse Event Reporting Program at www.FDA.gov/MedWatch/Report.htm.